On November 13, 2017 OncBioMune Pharmaceuticals, Inc. (OTCQB:OBMP) ("OncBioMune" or the "Company"), a revenue-stage biopharmaceutical company engaged in the development of a proprietary cancer vaccine technology, targeted cancer therapies and commercialization of a portfolio of products internationally, reported the latest data updating the progression results at 19 weeks for all 20 patients, who have completed 6 vaccines in their Phase 1 clinical trial of ProscaVax for recurrent prostate cancer patients with increasing prostate specific antigen (PSA) (Press release, OncBioMune Pharmaceuticals, NOV 13, 2017, View Source [SID1234522143]). ProscaVax is OncBioMune’s novel immunotherapeutic cancer vaccine consisting of a combination of prostate cancer associated PSA with the biological adjuvants interleukin-2 (IL-2) and granulocyte-macrophage colony-stimulating factor (GM-CSF).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
All 20 patients enrolled in the trial completed ProscaVax therapy per protocol and have now completed the first follow-up at 19 weeks. 16 of 20 patients (80%) demonstrated stable disease/no prostate cancer progression. Only four patients progressed during ProscaVax therapy (3 PSA progression, 1 radiological progression in the brain).
The safety review confirmed there were no drug-related serious adverse events or dose-limiting toxicities resulting from the vaccine therapy.
OncBioMune is awaiting additional follow-up data related to our previously disclosed study data. This includes additional results on patients beyond the previously reported 12 of 15 patients that received ProscaVax vaccine, who exhibited an increased immune response to PSA as determined with a Lymphocyte Blastogenesis Assay. Also, additional results on the 6 patients vaccinated after OncBioMune previously reported that 9 of 14 patients who received six ProscaVax vaccinations demonstrated increased PSA doubling times. Additional follow-up will provide longer follow-up intervals for the last six patients who completed the vaccine therapy.
"All the data to date is consistent with previous study data showing ProscaVax elicits immune responses to fight tumor growth in prostate cancer," said Dr. Jonathan Head, Chief Executive Officer at OncBioMune. "We are impressed that 80 percent of the patients treated with ProscaVax demonstrated stable disease. We look forward to continuing to follow the patients in this study to collect additional data and also to conducting a larger study to further validate the therapeutic benefit of our vaccine platform technology."